Fojo, Tito

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer

Drug Transport and Resistance MechanismsAntibiotic Resistance in Bacteria

Cited by 5,536

Tumour stem cells and drug resistance

Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer

Cancer Cells and MetastasisDrug Transport and Resistance Mechanisms

Cited by 3,668

Delivering affordable cancer care in high-income countries

Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology

Economic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life

Cited by 718

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia

Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K. (2012) · New England Journal of Medicine

Adrenal and Paraganglionic TumorsCancer, Hypoxia, and Metabolism

Cited by 397

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute

Economic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life

Cited by 349

Mitosis is not a key target of microtubule agents in patient tumors

Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology

Microtubule and mitosis dynamicsCancer Treatment and Pharmacology

Cited by 314

MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy

Patterson, E. E., Holloway, A. K., Weng, J., Fojo, T., & Kebebew, E. (2011) · Cancer

Adrenal and Paraganglionic TumorsMicroRNA in disease regulation

Cited by 171

Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

Rixe, O., & Fojo, T. (2007) · Clinical Cancer Research

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 147

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Laderian, B., & Fojo, T. (2017) · Seminars in Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 77

Liver resection and ablation for metastatic adrenocortical carcinoma

Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 62

BEZ235: When Promising Science Meets Clinical Reality

Pongas, G., & Fojo, T. (2016) · The Oncologist

Renal cell carcinoma treatmentStatistical Methods in Clinical Trials

Cited by 43